# Pertuzumab

## Perjeta inj 420mg/14mL

##### 臨採

| TAH Drug Code      | IPERJ                                                                                                                                                                                                                                                                                                                                                         |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | PERJETA (pertuzumab) is approved for use in combination with Herceptin (trastuzumab) and docetaxel (chemotherapy) in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.                                        |
| Dosing             | Initial dose of 840 mg infused over 60 minutes followed by a maintenance dose of 420 mg infused over 30-60 minutes every 3 weeks.                                                                                                                                                                                                                             |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                 |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                 |
| Contraindications  | Treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer.                                                                                                                                                                                                                                                               |
| Adverse Effects    | The most common side effects of PERJETA when given with Herceptin and docetaxel (chemotherapy) for treatment of breast cancer that has spread to other parts of the body (metastatic) are: Diarrhea Hair loss Low levels of white blood cells with or without a fever Nausea Feeling tired Rash Damage to the nerves (numbness, tingling, pain in hands/feet) |
| Pregnancy          | No Data                                                                                                                                                                                                                                                                                                                                                       |
| Lactation          | Human Data Suggest Potential Toxicity                                                                                                                                                                                                                                                                                                                         |

